YIMMUGO

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
YIMMUGO
Generic name
IMMUNE GLOBULIN INTRAVENOUS, HUMAN - DIRA
Manufacturer
Biotest AG
Product type
PLASMA DERIVATIVE
SPL set ID
77aaac18-f2af-46c4-8f65-b15be1cec3c2
SPL ID
50f8c921-beb0-c68b-e063-6294a90a8eb8
Version
6
Effective date
2026-03-01
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:40
Harmonized routes table
Harmonized routes
INTRAVENOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO [see Warnings and Precautions ( 5.3 ), Patient Counseling Information ( 17 )]. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose [see Warnings and Precautions ( 5.4 )] . For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Dosage and Administration ( 2.1 , 2.3 ), Warnings and Precautions ( 5.3 )] . WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. ( 5.3 ) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. ( 5.4 ) For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. ( 2.1 , 2.3 , 5.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS IgA-deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions to YIMMUGO. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions. ( 5.1 ) Hemolysis, either intravascular or due to enhanced red blood cell sequestration can develop subsequent to YIMMUGO treatments. Risk factors include high doses and non-O blood group. Closely monitor patients for hemolysis and hemolytic anemia. ( 5.2 ) In patients at risk of developing acute renal failure, monitor renal function, including blood urea nitrogen (BUN) and serum creatinine, and urine output. ( 5.4 ) Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment. ( 5.5 ) Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. ( 5.6 ) Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). ( 5.7 ) YIMMUGO is made from human blood and may contain infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.8 ) 5.1 Hypersensitivity Severe hypersensitivity reactions, including anaphylaxis, have been reported after YIMMUGO administration. [see Contraindications ( 4 )] . In case of hypersensitivity, discontinue YIMMUGO infusion immediately and institute appropriate treatment. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions. YIMMUGO contains less than or equal to 300 micrograms per milliliter of IgA [see Description ( 11 )] . Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. YIMMUGO is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity reaction [see Contraindications ( 4 )]. 5.2 Hemolysis Hemolysis has been reported after YIMMUGO administration. IGIV products, including YIMMUGO, may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and hemolysis. 1 Delayed hemolytic anemia can develop subsequent to IGIV treatment due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis.The following risk factors may be associated with the development of hemolysis following IGIV administration: high doses (e.g. ≥2 g/kg given either as a single administration or divided over several days), and non-O blood group. Other individual patient factors, such as underlying inflammatory state (as may be reflected by elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV, but their role is uncertain. Monitor patients for clinical signs and symptoms of hemolysis [see Patient Counseling Information ( 17 )] . If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit are observed after YIMMUGO infusion, perform confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with anemia after receiving IGIV, perform cross-matching to avoid exacerbating ongoing hemolysis. 5.3 Thrombosis Thrombosis may occur following treatment with immune globulin products, 2 , 3 including YIMMUGO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including patients with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Boxed Warning, Dosage and Administration ( 2 ), Patient Counseling Information ( 17 )] . 5.4 Renal Failure Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering YIMMUGO. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, hypovolemia, overweight, use of concomitant nephrotoxic drugs, or age of >65 years), administer YIMMUGO at the minimum infusion rate practicable [see Boxed Warning and Dosage and Administration ( 2.3 )]. Conduct periodic monitoring of renal function and urine output in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of YIMMUGO and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing YIMMUGO [see Patient Counseling Information ( 17 )]. 5.5 Hyperproteinemia, increased serum viscosity and hyponatremia Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV treatment, including YIMMUGO. It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thromboembolic events. 5.6 Aseptic Meningitis Syndrome Aseptic meningitis syndrome (AMS) may occur infrequently in patients following IGIV treatments, including YIMMUGO. AMS usually begins within several hours to 2 days following IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. 4 AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting [see Patient Counseling Information ( 17 )] . Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting signs and symptoms of AMS, including CSF studies, to rule out other causes of meningitis. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV. 5.7 Transfusion-Related Acute Lung Injury Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)] may occur in patients following IGIV treatment, 4 including YIMMUGO. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function and fever. Symptoms typically appear within 1 to 6 hours following treatment. Monitor patients for pulmonary adverse reactions. If TRALI is suspected immediately stop IGIV and perform appropriate tests for the presence of anti-neutrophil antibodies and anti-human leukocyte antigen (HLA) antibodies in both the product and the patient’s serum [see Patient Counseling Information ( 17 )] . TRALI is a potentially life-threatening condition requiring immediate intensive-care-unit management. TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.8 Transmissible Infectious Agents Because YIMMUGO is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. The risk of infectious agent transmission has been reduced by screening plasma donors and by including virus inactivation as well as virus and prion removal steps in the manufacturing process of YIMMUGO. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466). Discuss the risks and benefits of YIMMUGO use with patient before prescribing or administering this product. [see Patient Counseling Information ( 17 )] . 5.9 Monitoring Laboratory Tests Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of YIMMUGO and at appropriate intervals thereafter [see Warnings and Precautions ( 5.4 )] . Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis [see Warnings and Precautions ( 5.3 )] . If signs and/or symptoms of hemolysis are present after an infusion of YIMMUGO, perform appropriate laboratory testing for confirmation [see Warnings and Precautions ( 5.2 )] . If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and the patient's serum [see Warnings and Precautions ( 5.7 ) ]. 5.10 Interference with Laboratory Tests After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS . The most common adverse reactions in ≥5% of clinical trial patients were headache, upper respiratory tract infections, fatigue, nausea and increased blood pressure. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch​ 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Primary humoral immunodeficiency (PI) In an open-label, prospective, multicenter, multinational trial, the efficacy, safety, and pharmacokinetic properties of YIMMUGO as replacement therapy in patients with PI were investigated in 67 patients (including 12 children and 6 adolescents). 5,6 Patients received a dose between 200 mg to 800 mg per kg body weight (bw) every 3 or 4 weeks, for a treatment period of approximately 12 months. The initial dose and dosage interval was consistent with the patient’s prestudy IGIV treatment [see Clinical Studies ( 14 )]. There were two serious adverse events (SAEs) related to YIMMUGO, occurring in two patients: anaphylactic reaction, and severe neutropenia. Both SAEs led to discontinuation of YIMMUGO. One patient also had mild hemolysis and positive Coomb’s test. Adverse reactions (AR) occurring in ≥5% of patients are presented in Table 2. Table 2: Adverse Reactions* in ≥ 5% of Patients Adverse Reaction MedDRA - Preferred Term Number (%) of Patients with AR N = 67 Number (%) of Infusions N inf = 923 ≥1 Adverse reaction 39 (58) 93 (10) Headache 13 (19) 22 (2) Upper respiratory tract infections 8 (12) 8 (<1) Fatigue 5 (8) 8 (<1) Nausea 4 (6) 5 (<1) Increased blood pressure 4 (6) 4 <1) * Adverse reactions were identified as all AEs that were temporally associated with an infusion (occurred during infusion or within 72 h after the end of an infusion) or that were assessed as related. 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified and reported during the post-approval use of IGIV products: Respiratory: Apnea, Acute Respiratory Distress Syndrome (ARDS), TRALI, respiratory failure, hypoxemia, pulmonary edema, dyspnea, wheezing, cough, bronchospasm, pulmonary embolism. Cardiovascular: Cardiac arrest, thromboembolism, vascular collapse, hypotension, phlebitis, pallor, angina, tachycardia, bradycardia, palpitations, myocardial infarction, cyanosis. Neurological: Coma, loss of consciousness, seizures, (acute) encephalopathy, tremor, aseptic meningitis syndrome, migraine, speech disorder, paresthesia, hypoesthesia, photophobia. Integumentary: Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, eczema, erythematous rash, dermatitis, pruritus, alopecia, urticaria. Gastrointestinal: Hepatic dysfunction, abdominal pain, diarrhea. Renal: Acute renal failure, osmotic nephropathy, renal pain. Hematologic: Pancytopenia, leukopenia, hemolysis. Musculoskeletal: Musculoskeletal pain, muscle spasm, arthralgia, myalgia, muscle stiffness. General disorders and administration site conditions: Pyrexia, rigors, injection-site reactions, chills, flushing, lethargy, malaise, burning sensation. Psychiatric disorders: Confusion, anxiety, agitation, nervousness. Metabolic and nutritional: Fluid overload, (pseudo) hyponatremia. Immune system disorders: Hypersensitivity (e.g. anaphylaxis, allergic reaction), angioedema. Investigations: Falsely elevated erythrocyte sedimentation rate, positive direct antiglobulin (Coombs’) test, increased hepatic enzymes.

adverse reactions table

<table border="0"><tbody><tr><td><paragraph><content styleCode="bold">Adverse Reaction</content></paragraph><paragraph><content styleCode="bold">MedDRA - Preferred Term</content></paragraph></td><td><content styleCode="bold">Number (%) of Patients with AR N = 67 </content></td><td><content styleCode="bold">Number (%) of Infusions N <sub>inf </sub>= 923 </content></td></tr><tr><td><content styleCode="bold">&#x2265;1 Adverse reaction</content></td><td><content styleCode="bold">39 (58)</content></td><td><content styleCode="bold">93 (10)</content></td></tr><tr><td>Headache</td><td>13 (19)</td><td>22 (2)</td></tr><tr><td>Upper respiratory tract infections</td><td>8 (12)</td><td>8 (&lt;1)</td></tr><tr><td>Fatigue</td><td>5 (8)</td><td>8 (&lt;1)</td></tr><tr><td>Nausea</td><td>4 (6)</td><td>5 (&lt;1)</td></tr><tr><td>Increased blood pressure</td><td>4 (6)</td><td>4 &lt;1)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.